Drug Profile
Research programme: oral therapeutics - Chiasma
Alternative Names: CH 3; Chiasma Investigational Product 3; CHIP-3Latest Information Update: 10 Aug 2021
Price :
$50
*
At a glance
- Originator Chiasma
- Class Peptides; Proteins; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 05 Aug 2021 Chiasma has been acquired by Amryt Pharma
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in Israel (PO)
- 14 Oct 2015 Early research is ongoing in Israel